National Prostate Cancer Awareness Month is observed every September in the United States by health experts and advocates, and individuals concerned with men’s prostate health. Designating a month for the disease serves the purpose of increasing public awareness of the importance of prostate health and screenings, educating about risk factors and symptoms, and advocating for further research on prostate health issues.
Prostate cancer is the second most common cancer in American men. About one in seven men will be diagnosed with prostate cancer during his lifetime. According to the American Cancer Society, there will be about 174,650 new cases of prostate cancer and about 31,620 deaths from prostate cancer in the United States during the year 2019. There will be over 10,600 new cases of prostate cancer diagnosed in Texas alone.
There are several risk factors associated with prostate cancer, including family history, race, and diet, but the most common factor is age. Prostate cancer occurs mainly in older men. About six in ten cases are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.
While there are a lot of risk factors for prostate cancer, there are also good survival statistics associated with the disease. Survival rates for prostate cancer are very high. More than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.
At Austin CyberKnife, men diagnosed with prostate cancer are treated with the CyberKnife® Robotic Radiosurgery System. CyberKnife is a painless, non-invasive prostate cancer treatment technology in which high-dose radiation is delivered to the tumor from a linear accelerator mounted on a highly maneuverable robotic arm. Hundreds of different angles enable the radiation to be contoured to the shape of the prostate, resulting in treatment aimed directly to the prostate gland, avoiding nearby critical anatomy. This precision reduces treatment time to just five outpatient visits, compared to the average 45 visits conventional radiation therapy requires.